Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 101-106

  Shah, Anand P ^a   Strauss, Jonathan B ^a   Abrams, Ross A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; ESPAC; GITSG; Pancreatic cancer; Radiation

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; QUALITY OF LIFE; RADIATION DOSE; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 76749154477     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819171b9     Document Type: Review

References (54)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Eloubeidi MA, Desmond RA, Wilcox CM, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006; 192:322-329.
3. Li D, Xie K, Wolff R, et al. Pancreatic Cancer. Lancet. 2004;363:1049-1057.
4. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225: 621-633.
5. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
6. Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma. Semin Oncol. 2005;32(suppl 9):S30-S32.
7. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56-61.
8. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37:1519-1524.
9. Neoptolemos J, Stocken D, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med. 2004;350:1200-1208.
10. Bogoevski D, Yekebas EF, Schurr P, et al. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement. Ann Surg. 2004;240:993-1000.
11. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-962.
12. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who received chemotherapy. N Engl J Med. 1997;337:949-955.
13. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta analysis. J Clin Oncol. 1992;10:890-895.
14. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med. 1992;327:1618-1624.
15. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapychemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85-91.
16. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst. 1988;80:751-755.
17. Flickinger J, Jawalekar K, Deutsch M, et al. Split course radiation therapy for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1988;15:359-364.
18. Moertel C, Gunderson L, Mailliard J, et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. J Clin Oncol. 1994;12:21-27.
19. Kalser MH, Ellenberg SS. Pancreatic Cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
20. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
21. Klinkenbijl J, Jeekel J, Sahmound T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-784.
22. Smeenk, van Eijck, Hop, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246:734-740.
23. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Letter to editor. Ann Surg. 2006;244:332-333.
24. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
25. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
26. Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 2001;358:1565-1566.
27. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys. 1998;42:59-63.
28. Simon RM. Design and analysis of clinical trials. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Willliams & Wilkins; 2005:480-481.
29. Abrams RA, Winter KA, Regine WF, et al. RTOG 9704 - Radiotherapy Quality Assurance (QA) Review and Survival. Int J Radiat Oncol Biol Phys. 2006;66(suppl 3):S22.
30. Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298.
31. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins hospital. J Clin Oncol. 2008;26: 3503-3510.
32. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975- 2005). J Clin Oncol. 2008;26:3511-3516.
33. Greco JA, Castaldo ET, Feurer ID, et al. Survival benefit with adjuvant radiation therapy in surgically resected pancreatic cancer. Paper presented at: the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, 2007, Orlando, FL.
34. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
35. Tsao RE, Almhanna K, Lazzaryan A, et al. Is adjuvant radiation plus chemotherapy for resectable pancreatic adenocarcinoma associated with improved survival? The Cleveland Clinic experience. J Clin Oncol. 2008; 26(suppl): abstract 15528.
36. Burris HA, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
37. Neuhaus P, Riess H, Post S. CONKO-001: final results of the randomized, prospective multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2008;26(suppl): abstract LBA4504.
38. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil- based chemoradiation following resection of pancreatic adenocarcinoma- a randomized controlled trial. JAMA. 2008;299:1019-1026.
39. Lawrence T. Gemcitabine as a radiation sensitizer. Semin Oncol. 1995;22: 68-71.
40. Blackstock AW, Lightfoot H, Kwock L, et al. Gemcitabine: in vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dosing schedule- Preclinical observations relevant to gemcitabine clinical trials. Proc Am Soc Ther Radiol Oncol. 1997;39:205 abstract 141.
41. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208-2212.
42. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208.
43. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002;81:138-143.
44. Allen AM, Zalupski MM, Robertson JM, et al. Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys. 2004;59:1461-1467.
45. Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95:260-265.
46. Demols A, Peeters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian phase II study. Int J Radiat Oncol Biol Phys. 2005;62: 1351-1356.
47. Van Laethem JL, Demols A, Gay F, et al. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys. 2003;56:974-980.
48. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol. 2008;26 abstract 4506.
49. Picozzi VJ, Abrams RA, Traverso LW. ACOSOG Z05031: report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU and alpha-interferon. J Clin Oncol. 2008;26 abstract 4505.
50. Linehan D, Tan M, Strasberg S, et al. Adjuvant Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single institution phase II study. Ann Surg. 2008;248:145-151.
51. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine Chemotherapy and Single-Fraction Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. In press.
52. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-846.
53. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121-130.
54. Abrams RA. Comment on "adjuvant therapy in pancreatic cancer: a critical appraisal." Drugs. 2007;67:2481-2485; discussion 2491-2493.